XOMA (US) LLC (XOMA) Receives Orphan Drug Designation From U.S. FDA for Pyoderma Gangrenosum
2/25/2014 9:17:52 AM
BERKELEY, Calif., Feb. 24, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today gevokizumab, the Company's IL-1 beta modulating antibody, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of pyoderma gangrenosum (PG).
Help employers find you! Check out all the jobs and post your resume.
comments powered by